TW202340253A - 抗ｂｔｌａ抗體及其用途 - Google Patents

抗ｂｔｌａ抗體及其用途 Download PDF

Info

Publication number
TW202340253A
TW202340253A TW112103090A TW112103090A TW202340253A TW 202340253 A TW202340253 A TW 202340253A TW 112103090 A TW112103090 A TW 112103090A TW 112103090 A TW112103090 A TW 112103090A TW 202340253 A TW202340253 A TW 202340253A
Authority
TW
Taiwan
Prior art keywords
seq
sequence
antibody
antigen
monoclonal antibody
Prior art date
Application number
TW112103090A
Other languages
English (en)
Chinese (zh)
Inventor
李菊英
章乾
沈冰清
弗朗西斯科 阿德里安
連恩 施魏策爾
Original Assignee
香港商高誠生物醫藥（香港）有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 香港商高誠生物醫藥（香港）有限公司 filed Critical 香港商高誠生物醫藥（香港）有限公司
Publication of TW202340253A publication Critical patent/TW202340253A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Transplantation (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW112103090A 2022-01-29 2023-01-30 抗ｂｔｌａ抗體及其用途 TW202340253A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2022075109 2022-01-29
WOPCT/CN2022/075109 2022-01-29

Publications (1)

Publication Number Publication Date
TW202340253A true TW202340253A (zh) 2023-10-16

Family

ID=87470720

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112103090A TW202340253A (zh) 2022-01-29 2023-01-30 抗ｂｔｌａ抗體及其用途

Country Status (12)

Country Link
US (1) US20250388673A1 (enExample)
EP (1) EP4469482A4 (enExample)
JP (1) JP2025504543A (enExample)
KR (1) KR20240139083A (enExample)
CN (1) CN118871465A (enExample)
AR (1) AR128377A1 (enExample)
AU (1) AU2023212896A1 (enExample)
CA (1) CA3250219A1 (enExample)
IL (1) IL314579A (enExample)
MX (1) MX2024009309A (enExample)
TW (1) TW202340253A (enExample)
WO (1) WO2023143564A1 (enExample)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2097447A4 (en) * 2006-11-15 2010-12-29 Medarex Inc HUMAN MONOCLONAL ANTIBODIES AGAINST BTLA AND METHODS OF USE
BR112012007875A2 (pt) * 2009-07-31 2016-11-22 Medarex Inc anticorpos totalmente humanos para btla
MX2018010295A (es) * 2016-02-26 2019-06-06 Inst Nat Sante Rech Med Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
CN110790837A (zh) * 2018-08-02 2020-02-14 上海君实生物医药科技股份有限公司 抗btla抗体

Also Published As

Publication number Publication date
AU2023212896A1 (en) 2024-08-22
WO2023143564A1 (en) 2023-08-03
EP4469482A4 (en) 2026-05-06
AR128377A1 (es) 2024-04-24
US20250388673A1 (en) 2025-12-25
IL314579A (en) 2024-09-01
JP2025504543A (ja) 2025-02-12
MX2024009309A (es) 2024-08-27
CA3250219A1 (en) 2023-08-03
EP4469482A1 (en) 2024-12-04
KR20240139083A (ko) 2024-09-20
CN118871465A (zh) 2024-10-29

Similar Documents

Publication Publication Date Title
JP7474287B2 (ja) 炎症性腸疾患の治療を目的とする三剤併用療法
TWI564305B (zh) 治療性抗體
AU2016239858B2 (en) Antibodies to canine interleukin-4 receptor alpha
AU2022201425A1 (en) Anti-CD40 antibodies for use in treatment of Sjogren's syndrome
CA2977621A1 (en) Antibody binding to tfpi and composition comprising the same
JP2025518061A (ja) 抗ｂｄｃａ２抗体およびその使用
TW202523696A (zh) 抗-幹細胞因子抗體及其使用方法
KR20230117588A (ko) 다중특이적 항체 및 항체 조합
IL301625A (en) CD1A antibodies and their uses
EP4132582A1 (en) Targeted reduction of activated immune cells
TW202216195A (zh) April抗體分子及其用途
KR20220034775A (ko) 신규한 bssl 항체
US20250388673A1 (en) Antibody against btla and uses thereof
AU2023282504A1 (en) Igf1r antibodies
JP2025503707A (ja) ガレクチン－１０抗体
HK40114352A (zh) 针对btla的抗体及其用途
JP7525397B2 (ja) ネコＭｃＤｏｎｏｕｇｈ肉腫（ＦＭＳ）様チロシンキナーゼ３受容体リガンド（ＦＬＴ３Ｌ）に対する抗体並びに自己免疫疾患及び炎症性疾患を治療するためのそれらの使用
CN116670168A (zh) 针对april的抗体分子及其用途
JP7754841B2 (ja) ヒト化抗ヒトｃｄ８９抗体及びその使用
RU2826992C2 (ru) Новые антитела к bssl
WO2024211317A2 (en) Monoclonal antibodies to cadherin 11 and methods of use
WO2025222102A1 (en) Therapeutic combinations of acalabrutinib and a multispecific antibody to treat b-cell malignancies
EA052967B1 (ru) Антитела к ccr8 и способы их применения
EA051993B1 (ru) Гуманизированные антитела к cd89 человека и варианты их применения
EA052946B1 (ru) Антитела, содержащие только тяжелые цепи, которые связываются с cd22